Jumat, 29 Januari 2021

China will ‘no longer recognise’ UK passport for Hong Kong people - Al Jazeera English

Beijing’s announcement comes as Britain prepares to open its doors to millions of people from its former colony.

China on Friday said it will “no longer recognise” the British National (Overseas) passport for Hong Kong people, as the United Kingdom prepares to open its doors to millions more residents of its former colony following a Beijing security crackdown.

“From January 31, China will no longer recognise the so-called BNO passport as a travel document and ID document, and reserves the right to take further actions,” foreign ministry spokesman Zhao Lijian told reporters.

Beijing’s move to impose a national security law in June last year prompted Britain to offer refuge to almost three million Hong Kong residents eligible for BNO passport from January 31.

Al Jazeera’s Katrina Yu, reporting from Beijing, said the decision by China did not come as a surprise to many.

“Beijing has been mulling over this move for months and it is related to the national security law… [which] outlaws any separatism or any subversions against the government,” she said.

The Al Jazeera correspondent said dozens of people in Hong Kong have been arrested since the law was imposed.

Meanwhile, on Friday, the UK government promised to stand by the people of its former colony.

Holders of the BNO status – a legacy of UK rule over Hong Kong up to 1997 – will from Sunday be able to apply to live and work in the UK for up to five years, and eventually seek citizenship.

Before the change, BNO passport holders have had only limited rights to visit the UK for up to six months, and not to work or settle.

The UK says it is acting in response to a National Security Law imposed by China last year which has devastated Hong Kong’s democracy movement and shredded freedoms meant to last 50 years under the 1997 handover accord.

“I am immensely proud that we have brought in this new route for Hong Kong BN(O)s to live, work and make their home in our country,” Prime Minister Boris Johnson said in a statement.

“In doing so we have honoured our profound ties of history and friendship with the people of Hong Kong, and we have stood up for freedom and autonomy — values both the UK and Hong Kong hold dear.”

Any Hong Kong resident born before 1997 is eligible for BNO status. The new visa path opens up entry to the UK to an estimated 2.9 million adults in Hong Kong and another 2.3 million of their dependents.

Sino-British Joint Declaration

In practice, London projects that up to 322,400 of Hong Kong’s 7.5 million population will take up the visa over five years, benefitting the UK economy by up to 2.9 billion pounds ($4bn).

The new pathway will not come cheap.

A five-year visa will cost a relatively moderate 250 pounds ($342) per person. But a mandatory surcharge to access Britain’s state-run health service will run to 3,120 pounds ($4,268) per adult, and 2,350 pounds ($3,215) for those below 18.

Shorter, cheaper visas for 30 months will also be available.

“We have been clear we won’t look the other way when it comes to Hong Kong. We will live up to our historic responsibility to its people,” Foreign Secretary Dominic Raab said.

“China’s imposition of the National Security Law in Hong Kong constitutes a clear and serious breach of the [pre-handover] Sino-British Joint Declaration contrary to international law.”

The security law was imposed on Hong Kong last June in response to 2019 protests, targeting acts Beijing deems to be secession, subversion, terrorism or collusion with foreign forces.

Mass arrests of pro-democracy figures have followed. Some have fled Hong Kong for the West, including to Britain.

Between July 2020 and January 2021, about 7,000 people with BNO status and their dependents have already been given exceptional leave to live in the UK.

China, furious at Britain’s new visa pathway, has in turn accused London of flouting the handover agreement and demanded Western countries stay out of Hong Kong’s affairs.

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiZGh0dHBzOi8vd3d3LmFsamF6ZWVyYS5jb20vbmV3cy8yMDIxLzEvMjkvY2hpbmEtd2lsbC1uby1sb25nZXItcmVjb2duaXNlLXVrLXBhc3Nwb3J0LWZvci1ob25nLWtvbmdlcnPSAWhodHRwczovL3d3dy5hbGphemVlcmEuY29tL2FtcC9uZXdzLzIwMjEvMS8yOS9jaGluYS13aWxsLW5vLWxvbmdlci1yZWNvZ25pc2UtdWstcGFzc3BvcnQtZm9yLWhvbmcta29uZ2Vycw?oc=5

2021-01-29 09:55:00Z
52781337997531

EU warned by business group on plan to curb Covid vaccine exports - Financial Times

Brussels has been warned by a leading business group that its plans to give EU member states powers to block vaccine exports threatens to trigger retaliation and have a “devastating” impact on global jab supplies.

The International Chamber of Commerce said in a letter to Ursula von der Leyen, European Commission president, that the move to limit exports — which is expected as early as Friday — could “very rapidly erode essential supply chains”.

The warning came as the battle over scant supplies of Covid-19 jabs in rich countries intensifies, with Ms von der Leyen ramping up pressure on AstraZeneca, the company at the centre of controversy this week over vaccine availability.

Speaking to German radio, Ms von der Leyen said the company had not provided any “plausible explanation” for why it will not supply the agreed number of doses. The European Medicines Agency is expected to announce later on Friday whether it has approved the Oxford/AstraZeneca vaccine for use in the EU.

The ICC letter was prompted by commission plans to force companies to report all plans to export vaccines to national authorities, which would then have the power to stop shipments.

John Denton, ICC secretary-general, wrote: “Our immediate fear is that the proposed EU export controls risk triggering retaliatory actions by third countries that could very rapidly erode essential supply chains.

The letter, which is dated Thursday and has been seen by the Financial Times, went on: “Such a chain of events — which seems entirely foreseeable given the rapid escalation in trade barriers on personal protective equipment at the outset of the pandemic — would have devastating implications on the supply of vaccines globally, including across EU member states.”

Mr Denton, whose organisation represents more than 45m businesses worldwide, said the EU move — while “ultimately well-intentioned” — could also hurt poor countries that depend on manufacturing facilities in Europe for their supply. “I would encourage you to consider the potential effect of a prolonged pandemic in the developing world on the European economy,” he wrote.

The commission did not immediately respond to a request for comment on the ICC letter.

Europe’s main pharmaceutical industry association has also joined the business backlash against the Brussels proposals. The European Federation of Pharmaceutical Industries and Associations said Brussels’ plans could “undermine the supply of vaccines in Europe and around the world”.

“It is vital that any measures proposed by the Commission and the Member States do not restrict, hold back, or have other negative impacts on exports of vaccines or the import of key vaccine manufacturing supplies,” it said. “Risking retaliatory measures from other regions at this crucial moment in the fight against Covid-19 is not in anyone's best interest.”

In a widening EU effort to tighten its grip on vaccine supplies, Charles Michel, European Council president, has proposed the use of new legal powers and “enforcement measures” to ramp up jab production and address “severe difficulties” in the supply of certain products.

One EU official suggested the proposals, floated in a letter this week from Mr Michel to the leaders of four member states, could enable the bloc to require companies to share patents, licences and knowhow needed to broaden vaccine production.


Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiP2h0dHBzOi8vd3d3LmZ0LmNvbS9jb250ZW50LzI0ODY3ZDM5LTQ1MDctNGM0OC1iZTI3LWMzNGI1ODEyMjBiMNIBP2h0dHBzOi8vYW1wLmZ0LmNvbS9jb250ZW50LzI0ODY3ZDM5LTQ1MDctNGM0OC1iZTI3LWMzNGI1ODEyMjBiMA?oc=5

2021-01-29 09:33:00Z
52781329440642

Brazil’s COVID cases surpass nine million: Live Updates - Al Jazeera English

Brazil has vaccinated more than a million people but it is still less than 1 percent of the population, as the country is struggling to control a coronavirus case surge.

Hospitals are swamped with COVID-19 patients, with the city of Manaus, the gateway to the Amazon rain forest, still facing a shortage of oxygen in hospitals.

A fast-spreader COVID-19 strain detected in cities such as Manaus and Sao Paulo have thrown new challenges before authorities who have been accused of slow response.

On Friday, Novavax, a US-based company, announced that its coronavirus vaccine appears to be 89 percent effective based on early findings from a British study, and that it also seems to work – though not as well – against new mutated versions of the virus circulating in the United Kingdom and South Africa.

Africa can expect that at least 30 percent of its population will be immunised by the end of 2021, said the World Health Organization as vaccines begin trickling into the continent.

Worldwide, the pandemic has killed more than two million people and infected nearly 101 million, according to data from the Johns Hopkins University.

Hello, this is Virginia Pietromarchi in Rome, Italy, giving you the latest updates on the coronavirus pandemic:

Dengvaxia controversy haunts Duterte’s vaccine roll out

Gene Nisperos is an associate professor at the University of the Philippines (UP) College of Medicine in the country’s capital, Manila. As a medical frontliner, he is on the priority list for vaccination against the coronavirus when the government releases its promised first vaccines next month.

But Nisperos has grave doubts about President Rodrigo Duterte’s plan. The medic is particularly critical of the government’s decision to disallow Filipinos from choosing the type of coronavirus vaccine they receive.

To get to know more, read the full story here.


Malaysia’s latest figures

Malaysia reported 5,725 new coronavirus cases, the highest daily increase since the start of the pandemic a year ago.

The new cases took the cumulative total of infections past the 200,000 mark. Health authorities also reported 16 deaths, raising total fatalities to 733.

A family member of a victim of the coronavirus disease (COVID-19) prays after a burial at a cemetery, in Batu Caves, Malaysia [Lim Huey Teng/Reuters]

WHO team visits hospital in Wuhan amid ongoing probe

A WHO-led team of experts investigating the origins of COVID-19 visited a hospital in the Chinese city of Wuhan that was one of the first to treat patients in the early days of the outbreak.

The team went to the Hubei Provincial Hospital of Integrated Chinese and Western Medicine where Zhang Jixian, director of the hospital’s department of respiratory and critical care, has been cited by state media as the first to report the novel coronavirus, after treating an elderly couple in late 2019 whose CT scans showed differences from typical pneumonia.

“Extremely important 1st site visit. We are in the hospital that treated some of the first known cases of COVID-19, meeting with the actual clinicians & staff who did this work, having open discussion about the details of their work,” Peter Daszak, a member of the WHO-led team, wrote on Twitter.

The team was released from two weeks of quarantine on Thursday. It plans to visit labs, markets and hospitals during its remaining two weeks in Wuhan, where the coronavirus was first identified in late 2019.


Germany expects ‘limits’ on EMA AstraZeneca approval

Germany expects EU regulator EMA to impose restrictions when it authorises the use of the AstraZeneca vaccine in the bloc as efficacy data for older people are insufficient, said Health Minister Jens Spahn.

“We’re not expecting an authorisation without limits,” he told a press conference.

The EMA is on Friday due to approve the vaccine developed with the University of Oxford. However, questions remain about how well the AstraZeneca vaccine protects older people. Only 12 percent of the participants in its research were over 55 and they were enrolled later, so there hasn’t been enough time to get results.

Germany’s vaccine commission said on Thursday it could not recommend the use of the jabs on people aged 65 years and older because efficacy data for the group were lacking. Britain’s medicines regulatory agency also acknowledged the limited data in older people but still cleared the shot last month for all adults, with some caution for pregnant women.


EU chief wants to publish AstraZeneca contract

The European Commission plans to publish a redacted copy of its contract with drugs giant AstraZeneca, EU chief Ursula von der Leyen said, amid a dispute over delays to vaccine deliveries.

“We want to publish it today. We are talking to the company about which parts have to be blacked out,” she told German broadcaster Deutschlandfunk.


Vietnam to begin mass testing

Vietnam will conduct mass testing for COVID-19 in the northern province of Hai Duong, the epicentre of a new outbreak of the coronavirus, and other affected areas, according to deputy health minister Nguyen Truong Son.

Vietnam has reported 93 locally transmitted infections since the outbreak emerged on Thursday, most linked to an electronics factory in the province. In a statement on the government’s website, Son said most of the remaining 2,340 workers at the factory had subsequently tested negative for the virus.

A health worker takes a swab sample from a resident, amid the coronavirus disease (COVID-19) outbreak, in Hai Duong province, Vietnam [Manh Minh/VNA/Handout via Reuters]

UK to not disclose vaccine contract due to national security risk: junior minister

Britain will not publish the vaccine contract it has with AstraZeneca because it would risk national security, said a junior minister.

“Where it is appropriate for the public to be informed we have done so but if that risks national security for any reason, of course, we should not, ” British prisons minister Lucy Frazer said when asked why the government was worried about the publication of the contract.

Pressed further on the risk to national security, she said: “Well, that is my understanding,” he told LBC Radio.


UK bans UAE flights

Britain is banning direct passenger flights to and from the United Arab Emirates (UAE) from Friday, shutting down the world’s busiest international airline route from Dubai to London.

Britain said it was adding the UAE, Burundi and Rwanda to its coronavirus travel ban list because of worries over the spread of a more contagious and potentially vaccine-resistant COVID-19 variant first identified in South Africa.

Read the full story here.


Novavax says vaccine 89 percent effective in UK trial

Biotech company Novavax has said its coronavirus vaccine was 89.3 percent effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the UK, according to a preliminary analysis.

A mid-stage trial of the vaccine in South Africa, where a troubling new variant of the virus is common, showed 60 percent effectiveness among people who did not have HIV.

Novavax shares surged 34 percent in after-hours trading following the release of the trial results on the same day the United States reported its first cases of the South African variant.

Read the full story here.


Brazil struggles to contain the outbreak

Brazil has vaccinated more than a million people, but that is less than 1 percent of the population. The country is struggling to contain the coronavirus and the situation seems far from resolving as a fast-spreader variant of the virus has already been detected in large cities such as Sao Paulo.

The Amazonas state’s capital, Manaus, is facing a shortage of oxygen with healthcare workers working around the clock to prevent patients from suffocating to death.

“You ask a nurse to help you and she says she can’t do anything because she is dealing with another patient who is dying in front of you,” said mourner Valceny Ferreira. “There aren’t enough healthcare workers to deal with this, but we wouldn’t be in this state if the Amazonas state would have invested in the healthcare,” she added.

Researches say the variant of the coronavirus detected in Japan originating in the Brazilian state of Amazonas is already dominant in its capital Manaus, reinforcing initial suspicions that it may be more contagious [Marcio James/AFP]

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiYGh0dHBzOi8vd3d3LmFsamF6ZWVyYS5jb20vbmV3cy8yMDIxLzEvMjkvYnJhemlscy1jb3ZpZC1jYXNlcy1zdXJwYXNzZXMtbmluZS1taWxsaW9uLWxpdmUtdXBkYXRlc9IBZGh0dHBzOi8vd3d3LmFsamF6ZWVyYS5jb20vYW1wL25ld3MvMjAyMS8xLzI5L2JyYXppbHMtY292aWQtY2FzZXMtc3VycGFzc2VzLW5pbmUtbWlsbGlvbi1saXZlLXVwZGF0ZXM?oc=5

2021-01-29 09:12:27Z
52781338842931

COVID-19: Brussels has 'binding orders' for AstraZeneca jab, says EU chief - Sky News

A contract between Brussels and AstraZeneca for its COVID-19 vaccine contains binding orders, EU chief Ursula von der Leyen has said.

Her comments come amid the deepening row with the drug giant over supply shortages, as European regulators are poised to approve the coronavirus jab.

The threat of legal action has been raised by the EU to secure COVID-19 vaccine stocks if talks over delayed deliveries fail.

Live COVID updates from the UK and around the world

Please use Chrome browser for a more accessible video player

EU pressures Astra Zeneca over shortfall

Brussels has demanded doses be sent from UK plants to make up for a shortfall, but Cabinet Office Minister Michael Gove said the government will not allow vaccines intended for Britain to go to the bloc.

On Friday, an EU source said AstraZeneca has offered an additional eight million COVID-19 vaccine doses in the first quarter this year.

The EU also plans to tighten oversight of vaccine exports.

More from Covid-19

Brussels has faced criticism and growing public frustration over the slow rollout of jabs as the UK, which is looking to approve its fourth vaccine, has raced ahead.

Ramping up the war of words, Ms Von der Leyen told German radio the best-effort delivery clause in the contract was only valid as long as it was not clear whether AstraZeneca could develop a vaccine.

She said the deal contained very clear delivery amounts for December and the first three quarters of 2021, and also mentioned four production sites, two of which are in Britain.

"There are binding orders and the contract is crystal clear," she said.

Meanwhile, European Council President Charles Michel has also said the EU should consider legal means to ensure supplies.

Subscribe to the All Out Politics podcast on Apple Podcasts, Google Podcasts, Spotify, Spreaker

Mr Michel, who represents the EU's 27 member states, said in a letter to a number of national leaders: "So far the explanations provided by some pharmaceutical companies have not provided us with the reassurances we need.

"While continuing dialogue, I believe the EU needs to take robust action to secure its supply of vaccines and demonstrate concretely that the protection of its citizens remains our absolute priority.

"In this regard, I welcome the commission's proposal for an export transparency mechanism which could be an instrument to ensure that vaccine doses originally intended for member states are not unduly exported.

"In addition, I support all efforts to resolve the matter with companies through dialogue and negotiation."

He added: "However, if no satisfactory solution can be found, I believe we should explore all options and make use of all legal means and enforcement measures at our disposal.

"I believe this solution would demonstrate the EU's strength and reliability in protecting its citizens' health over and above all other considerations."

Over three nights, Sky News will host a series of special programmes examining the UK's response to the pandemic.

Watch COVID Crisis: Learning the Lessons at 8pm on 9, 10 and 11 February.

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiamh0dHBzOi8vbmV3cy5za3kuY29tL3N0b3J5L2NvdmlkLTE5LWJydXNzZWxzLWhhcy1iaW5kaW5nLW9yZGVycy1mb3ItYXN0cmF6ZW5lY2EtamFiLXNheXMtZXUtY2hpZWYtMTIyMDE5MTbSAW5odHRwczovL25ld3Muc2t5LmNvbS9zdG9yeS9hbXAvY292aWQtMTktYnJ1c3NlbHMtaGFzLWJpbmRpbmctb3JkZXJzLWZvci1hc3RyYXplbmVjYS1qYWItc2F5cy1ldS1jaGllZi0xMjIwMTkxNg?oc=5

2021-01-29 09:00:08Z
52781329440642

Novavax vaccine – New 89% effective Covid jab works on UK and South Africa strains – and we’ve ordered 60m - The Sun

A NEW Covid jab for Britain is effective in 89.3 per cent of cases, it was revealed last night.

Sixty million doses of the Novavax vaccine will be produced on Teesside — as the EU is trying to scupper exports of jabs.

😷 Read our coronavirus live blog for the latest news & updates

Britain celebrates a vaccine boost with 150million doses on the way
Britain celebrates a vaccine boost with 150million doses on the wayCredit: SWNS:South West News Service

The drug, shown in UK trials to be effective against the Kent variant of Covid, was hailed by PM Boris Johnson.

Britain's incredible vaccine campaign got a triple boost with the news of 150million extra jabs.

The Government has secured 60million doses of the drug — which experts said was also 85.6 per cent effective against the sweeping UK variant of Covid-19.

The Sun can reveal results of trials for the one-shot US Janssen vaccine are expected imminently — with Britain having ordered 30million doses.

A French firm is using a Scottish factory to produce another 60million doses of a promising vaccine.

It means 120million of the extra jabs will be UK-produced.

Approval of the Novavax vaccine is likely to come next month
Approval of the Novavax vaccine is likely to come next monthCredit: SWNS:South West News Service

It came as figures showed 7,447,199 Brits have now received their first does, and 476,298 have had their second.

The Novavax jab’s 89.3 per cent efficacy in UK trials was called “spectacular” by expert Clive Dix.

It is likely to be approved next month and will be manufactured in Stockton-on-Tees for use this summer. The factory, owned by Fujifilm, has capacity to ramp up production to 180million doses.

Novavax boss Stanley Erck said it has been shown to work against “UK and South Africa variants”.

Vaccine Minister Nadhim Zahawi, one of 15,000 UK volunteers to take part in the Novavax trials, said: “I am particularly thrilled to see such positive results.”

Health Secretary Matt Hancock said: “If approved by the regulator, the vaccine will be a significant boost and another weapon in our arsenal to beat this awful virus.

'UK AT THE FOREFRONT OF ANOTHER MEDICAL BREAKTHROUGH'

“I’m proud the UK is at the forefront of another medical breakthrough and I want to thank the brilliant scientists and researchers, as well as the tens of thousands of selfless volunteers who took park in clinical trials.

“The NHS stands ready to roll this vaccine out as quickly as possible if it is authorised.”

PM Boris Johnson said it was “good news”.

Meanwhile French firm Valneva has started large-scale manufacturing of its vaccine in Livingston, West Lothian.

It can supply up to 250million shots annually. On top of this, US tests on the Janssen vaccine are expected to pave the way for 30million doses to start arriving in the UK as early as July.

Janssen is the Belgium-based vaccine arm of US pharmaceutical giant Johnson & Johnson.

The drug has been hailed by PM Boris Johnson
The drug has been hailed by PM Boris JohnsonCredit: AFP or licensors
Vaccine Minister Nadhim Zahawi was one of 15,000 UK volunteers to take part in the Noravax trials
Vaccine Minister Nadhim Zahawi was one of 15,000 UK volunteers to take part in the Noravax trialsCredit: PA:Press Association

Through its Vaccines Taskforce, the UK has now secured early access to 367million jabs.

There was further good news when Israel announced that less than 0.04 per cent of patients who received two doses of the Pfizer vaccine have developed Covid.

But holidays to European hotspots will be off until they sort their shambolic vaccination rollout. Senior cabinet minister Michael Gove has hinted that stricter border measures could be in place for months, even after the UK comes out of lockdown.

The jab will be manufactured in Stockton-on-Tees for use this summer
The jab will be manufactured in Stockton-on-Tees for use this summerCredit: Reuters

Yesterday the UAE, a favourite of social media influencers, was added to 30 no-go countries.

An estimated 24,000 Brits across the globe now face dashing back to avoid having to quarantine in hotels on arrival, expected to be imposed on February 8. But for the next week, arrivals will have to isolate for ten days at home.

Mr Gove said: “I think it’s important to stress that people shouldn’t expect any premature lifting of these restrictions.”

Novavax CEO Stanley Erck explains how new Covid vaccine will work

GOT a story? RING The Sun on 0207 782 4104 or WHATSAPP on 07423720250 or EMAIL exclusive@the-sun.co.uk

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiR2h0dHBzOi8vd3d3LnRoZXN1bi5jby51ay9uZXdzLzEzODgyMTEyL25vdmF2YXgtdmFjY2luZS11ay1jb3ZpZC1zdHJhaW4v0gFLaHR0cHM6Ly93d3cudGhlc3VuLmNvLnVrL25ld3MvMTM4ODIxMTIvbm92YXZheC12YWNjaW5lLXVrLWNvdmlkLXN0cmFpbi9hbXAv?oc=5

2021-01-29 08:19:00Z
52781338842931

Covid: AstraZeneca contract must be published, says European Commission chief - BBC News

European Commission chief Ursula von der Leyen
Reuters

The head of the European Commission, Ursula von der Leyen, has called for the EU's vaccine contract with drug-maker AstraZeneca to be published, in a growing row over reduced supplies.

The contract signed in August contained "binding orders", she told German radio, and she demanded "plausible explanations" for the hold-ups.

UK-Swedish AstraZeneca is blaming production delays at two plants.

Its vaccine is expected to be approved by the EU medicines regulator later.

The August deal was for 300 million doses for the European Union to be delivered after regulatory approval, with an option for 100 million more.

But EU sources say they now expect to get only about a quarter of the 100 million vaccines they were expecting to receive by March, a shortfall of about 75 million jabs.

AstraZeneca says the production problems are at its plants in the Netherlands and Belgium.

Its chief executive, Pascal Soriot, has said that the contract stipulated that the company would make its "best effort" to meet the EU demand and did not compel the company to stick to a specific timetable.

The EU is under pressure after criticism that the pace of vaccine distribution in several member countries is too slow.

"There are binding orders and the contract is crystal clear," Mrs von der Leyen said in Friday morning's radio interview.

"AstraZeneca has also explicitly assured us in this contract that no other obligations would prevent the contract from being fulfilled," she said.

Vaccine doses in EU, 28 Jan 21

The company is producing the jab at its UK plants too and there have been no problems with its contract with the UK authorities.

Mrs von der Leyen said two UK plants were mentioned in the contract as production sites for vaccine destined for the EU.

On her call for the contract to be published, she demanded transparency: "We are speaking with the company about which parts need to be redacted. But we want to achieve transparency."

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiMGh0dHBzOi8vd3d3LmJiYy5jby51ay9uZXdzL3dvcmxkLWV1cm9wZS01NTg1MjY5ONIBNGh0dHBzOi8vd3d3LmJiYy5jby51ay9uZXdzL2FtcC93b3JsZC1ldXJvcGUtNTU4NTI2OTg?oc=5

2021-01-29 08:05:00Z
52781329440642

Kamis, 28 Januari 2021

COVID-19: How the Novavax vaccine works - and the benefits it has over the three already approved - Sky News

A jab made by the US firm Novavax could become the fourth vaccine to be approved in the UK after promising data from a late-stage trial emerged.

Nearly 7.5 million people across the UK have received their first dose of a coronavirus vaccine - with the nationwide rollout seen as the country's best hope of bringing the pandemic to an end.

The Pfizer/BioNTech and Oxford/AstraZeneca jabs are already being distributed, while the Moderna vaccine has been given the green light for use.

But what is so different about the Novavax vaccine - and how many doses has the UK ordered?

More than 15,000 people aged 18 to 84 took part in the Phase 3 clinical trial in the UK. Pic: AP
Image: More than 15,000 people aged 18 to 84 took part in the Phase 3 clinical trial in the UK. Pic: AP

How effective is the Novavax vaccine?

Phase 3 trials of the experimental vaccine suggest it is 89.3% effective against COVID-19.

The vaccine candidate was shown to be 95.6% effective against the original strain of coronavirus, and 85.6% effective against the variant first detected in the UK.

The study involved more than 15,000 participants aged 18 to 84, with 27% aged over 65.

Does it work against the South Africa variant?

An early stage study was carried out on 4,400 people in South Africa, including some volunteers with HIV.

Among the HIV-negative volunteers, the vaccine appears to be 60% effective. When immune-compromised volunteers are included, the jab offered 49% protection overall.

Novavax plans to immediately start development on a vaccine specifically targeted to the South African variant.

A nurse holding the Pfizer/BioNTech COVID-19 vaccine in Coventry
Image: The Novavax jab is different from others already approved for use in the UK, such as the Pfizer vaccine

How does the vaccine work?

The Novavax vaccine differs from those already being used in the UK.

It combines an engineered protein from the virus that causes COVID-19 with a plant-based ingredient to help generate a stronger immune response.

If the body encounters coronavirus in the future, the body is primed to fend it off.

How many doses will be available?

The UK has ordered 60 million vials of the vaccine.

They will be manufactured at the Fujifilm plant in Stockton-on-Tees.

Subscribe to the All Out Politics podcast on Apple Podcasts, Google Podcasts, Spotify, Spreaker

How many doses of the vaccine will each person need?

People will be given two doses of the vaccine, three weeks apart.

How is it stored?

The Novavax vaccine, called NVX-CoV2373, only needs to be stored at fridge temperatures - much like the AstraZeneca and Moderna vaccines.

This means distribution and supply chain management is easier than it is for the Pfizer vaccine, which has to be stored at the much lower temperature of -70C.

How much will it cost the UK government?

The treatment comes at a cost of $16 (£11.66) per vaccination.

The jab is therefore more expensive than the AstraZeneca vaccine, but cheaper than both Pfizer and Moderna treatments.

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMicGh0dHBzOi8vbmV3cy5za3kuY29tL3N0b3J5L2NvdmlkLTE5LXdoYXQtaXMtdGhlLW5vdmF2YXgtdmFjY2luZS1hbmQtaG93LWRvZXMtaXQtY29tcGFyZS13aXRoLXRoZS1vdGhlcnMtMTIyMDE3OTnSAXRodHRwczovL25ld3Muc2t5LmNvbS9zdG9yeS9hbXAvY292aWQtMTktd2hhdC1pcy10aGUtbm92YXZheC12YWNjaW5lLWFuZC1ob3ctZG9lcy1pdC1jb21wYXJlLXdpdGgtdGhlLW90aGVycy0xMjIwMTc5OQ?oc=5

2021-01-29 02:48:45Z
52781336665716